Polymyxin B (Sulfate)

O=S(O)(O)=O.O=C(N[C@H](C(N[C@@](C(N[C@H](C(N[C@@]1([H])[C@H](O)C)=O)CCN)=O)([H])CCN)=O)CC(C)C)[C@H](NC([C@@H](NC([C@@](CCNC1=O)([H])NC([C@H](CCN)NC([C@H]([C@H](O)C)NC([C@H](CCN)NC(CCCCC(C)C)=O)=O)=O)=O)=O)CCN)=O)CC2=CC=CC=C2.O=C(N[C@H](C(N[C@@](C(N[C@H](C(N[C@@]3([H])[C@H](O)C)=O)CCN)=O)([H])CCN)=O)CC(C)C)[C@H](NC([C@@H](NC([C@@](CCNC3=O)([H])NC([C@H](CCN)NC([C@H]([C@H](O)C)NC([C@H](CCN)NC(CCCC[C@@H](C)CC)=O)=O)=O)=O)=O)CCN)=O)CC4=CC=CC=C4

[1]Danner RL, et al. Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob Agents Chemother. 1989 Sep;33 (9) :1428-34.|[2]Landersdorfer CB, et al. Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. J Antimicrob Chemother. 2018 Feb 1;73 (2) :462-468. |[3]Vingsbo Lundberg C, et al. Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice. J Antimicrob Chemother. 2010 May;65 (5) :981-5.

ACS Nano. 2021 Mar 23;15 (3) :4173-4185.|Agronomy. 2024 Feb 8, 14 (2), 351.|bioRxiv. 2024 Dec 2:2024.11.27.625634.|bioRxiv. 2024 May 10.|Int J Pharm. 2022 Jan 25:612:121356.|J Antimicrob Chemother. 2020 Sep 1;75 (9) :2609-2615.|Mater Today Bio. 2025 Feb 18:31:101590.|Microbiol Spectr. 2022 Apr 27;10 (2) :e0273021.|Transl Psychiatry. 2022 Apr 7;12 (1) :146.|ArXiv. 2025 Nov 7.|Biomed Pharmacother. 2023 Dec 31:169:115856.|bioRxiv. 2025 January 19.|Infect Genet Evol. 2025 Sep:133:105780.|Int J Antimicrob Agents. 2025 Jun 9:107551.|iScience. 2024 Sep 24;27 (10) :111027.|J Control Release. 2025 May 30:113907.|J Nanobiotechnology. 2025 Jul 1;23 (1) :465.|Prince of Songkla University. 2023 Dec.